
## Antonio Pagliuca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8387142/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2016, 51, 906-912.	1.3	364
2	The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood, 2000, 96, 3932-3938.	0.6	319
3	Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari Syndrome. Gastroenterology, 2006, 130, 2031-2038.	0.6	265
4	<scp>BCSH</scp> / <scp>BSBMT</scp> guideline: diagnosis and management of venoâ€occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. British Journal of Haematology, 2013, 163, 444-457.	1.2	254
5	Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation, 2018, 53, 138-145.	1.3	225
6	Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem ell transplantation. British Journal of Haematology, 2011, 155, 318-327.	1.2	205
7	Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood, 2004, 104, 1616-1623.	0.6	199
8	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	6.9	189
9	BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 2004, 103, 428-434.	0.6	171
10	Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood, 2011, 118, 2351-2357.	0.6	148
11	Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood, 2002, 99, 4370-4378.	0.6	141
12	Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology, 1997, 99, 939-944.	1.2	137
13	Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood, 2000, 96, 1239-1246.	0.6	136
14	Repression of transcriptional activity at a distance by the evolutionary conserved KRAB domain present in a subfamily of zinc finger proteins. Nucleic Acids Research, 1994, 22, 2908-2914.	6.5	132
15	Outcomes of Allogeneic Hematopoietic Cell Transplantation inÂPatients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biology of Blood and Marrow Transplantation, 2016, 22, 432-440.	2.0	127
16	Peripheral Blood Hematopoietic Stem Cells for Transplantation of Hematological Diseases from Related, Haploidentical Donors after Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 890-895.	2.0	126
17	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. Journal of Infection, 2018, 76, 20-37.	1.7	125
18	Liver transplantation for budd-chiari syndrome. Transplantation, 2002, 73, 973-977.	0.5	124

#	Article	IF	CITATIONS
19	Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood, 2002, 100, 1715-1720.	0.6	117
20	Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood, 2003, 103, 1152-1157.	0.6	116
21	Nonmyeloablative Peripheral Blood Haploidentical Stem Cell Transplantation for Refractory Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1711-1716.	2.0	106
22	Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplantation, 2008, 42, 783-789.	1.3	105
23	â€~Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. British Journal of Haematology, 1998, 103, 1075-1082.	1.2	100
24	Correction of the Hyper-IgM Syndrome after Liver and Bone Marrow Transplantation. New England Journal of Medicine, 2000, 342, 320-324.	13.9	99
25	Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. British Journal of Haematology, 1989, 71, 499-504.	1.2	94
26	Interferon α and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. British Journal of Haematology, 2001, 113, 779-784.	1.2	91
27	Poor outcome and prolonged persistence of SARS oVâ€2 RNA in COVIDâ€19 patients with haematological malignancies; King's College Hospital experience. British Journal of Haematology, 2020, 190, e279-e282.	1.2	89
28	Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. Biology of Blood and Marrow Transplantation, 2019, 25, 443-450.	2.0	84
29	Allogeneic peripheral blood stem cell transplantation for haematological malignancies – an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplantation, 1997, 19, 9-13.	1.3	83
30	Diverging effects of HLA–DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia, 2010, 24, 58-65.	3.3	83
31	Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. British Journal of Haematology, 2002, 119, 144-154.	1.2	79
32	Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. British Journal of Haematology, 2016, 172, 360-370.	1.2	79
33	Outcome of Donor Lymphocyte Infusion after T Cell–depleted Allogeneic Hematopoietic Stem CellÂTransplantation for Acute Myelogenous LeukemiaÂandÂMyelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2013, 19, 562-568.	2.0	78
34	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. Biology of Blood and Marrow Transplantation, 2016, 22, 1874-1882.	2.0	78
35	Quality rather than quantity: the cord blood bank dilemma. Bone Marrow Transplantation, 2010, 45, 970-978.	1.3	74
36	Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 1990, 4, 486-9.	3.3	73

#	Article	IF	CITATIONS
37	Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leukemia Research, 2010, 34, 723-727.	0.4	70
38	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood, 2022, 139, 1588-1592.	0.6	70
39	Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. Blood, 2015, 126, 1027-1032.	0.6	69
40	Use of Zidovudine and Interferon Alfa With Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia/Lymphoma. Journal of Clinical Oncology, 2011, 29, 4696-4701.	0.8	68
41	Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2014, 49, 42-48.	1.3	65
42	A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. European Journal of Haematology, 2007, 78, 532-539.	1.1	63
43	Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?. Haematologica, 2009, 94, 536-541.	1.7	63
44	Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of 533 Adult Patients Who Underwent Transplantation at King's College Hospital. Biology of Blood and Marrow Transplantation, 2015, 21, 60-66.	2.0	62
45	Primary myelodysplastic syndrome in children: the clinical experience in 33 cases. British Journal of Haematology, 1992, 82, 347-353.	1.2	61
46	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplantation, 2020, 55, 485-495.	1.3	61
47	Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplantation, 2012, 47, 824-830.	1.3	58
48	Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. British Journal of Haematology, 1998, 100, 784-792.	1.2	56
49	Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. British Journal of Haematology, 2006, 135, 201-209.	1.2	56
50	A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transplantation, 2015, 50, 62-67.	1.3	56
51	The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. British Journal of Haematology, 2006, 134, 385-390.	1.2	55
52	Eczematoid Graft-vs-Host Disease. Archives of Dermatology, 2007, 143, 1157-62.	1.7	55
53	FoxP3 <sup>+</sup> regulatory T cells are distinct from leukemia cells in HTLVâ€l–associated adult Tâ€cell leukemia. International Journal of Cancer, 2009, 125, 2375-2382.	2.3	55
54	Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplantation, 2010, 45, 1502-1507.	1.3	51

#	Article	IF	CITATIONS
55	Lead poisoning: clinical, biochemical, and haematological aspects of a recent outbreak Journal of Clinical Pathology, 1990, 43, 277-281.	1.0	50
56	A comprehensive diagnostic approach using galactomannan, targeted βâ€ <scp>d</scp> â€glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients. British Journal of Haematology, 2015, 168, 219-229.	1.2	49
57	COVIDâ€19â€induced endotheliitis: emerging evidence and possible therapeutic strategies. British Journal of Haematology, 2021, 193, 43-51.	1.2	49
58	Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. Journal of Medical Virology, 2006, 78, 1560-1563.	2.5	48
59	Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplantation, 2010, 45, 633-639.	1.3	47
60	Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infectious Diseases, 2015, 15, 128.	1.3	46
61	Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. Lancet Haematology,the, 2019, 6, e276-e284.	2.2	46
62	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood Advances, 2022, 6, 2427-2433.	2.5	46
63	The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders. Transplantation, 2012, 94, 784-793.	0.5	45
64	Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants. Bone Marrow Transplantation, 2017, 52, 717-725.	1.3	45
65	Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges. British Journal of Dermatology, 2007, 156, 1032-1038.	1.4	44
66	Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. British Journal of Haematology, 2008, 141, 235-243.	1.2	44
67	Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms. Blood Advances, 2018, 2, 36-48.	2.5	44
68	MANAGEMENT OF ADULT T-CELL LEUKAEMIA/LYMPHOMA. British Journal of Haematology, 1998, 100, 453-458.	1.2	43
69	Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London. British Journal of Cancer, 2021, 125, 939-947.	2.9	41
70	The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. Journal of Hepatology, 1997, 27, 1015-1021.	1.8	40
71	Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning - evidence for a superior outcome using melphalan combined with total body irradiation. British Journal of Haematology, 2005, 128, 496-502.	1.2	40
72	High Fever Occurring 4 to 5 Days Post-Transplant of Haploidentical Bone Marrow or Peripheral Blood Stem Cells after Reduced-Intensity Conditioning Associated with the UseÂof Post-Transplant Cyclophosphamide as Prophylaxis for Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 197-198.	2.0	40

#	Article	IF	CITATIONS
73	<pre><scp>BCSH</scp>/<scp>BSBMT</scp>/<scp>UK</scp> clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. British Journal of Haematology, 2016, 173, 380-393.</pre>	1.2	40
74	A national service for delivering <scp>CD19 CARâ€T</scp> in large Bâ€cell lymphoma – The <scp>UK</scp> realâ€world experience. British Journal of Haematology, 2022, 198, 492-502.	1.2	40
75	Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. British Journal of Haematology, 2007. 138. 517-526.	1.2	39
76	Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. Bone Marrow Transplantation, 2016, 51, 1599-1601.	1.3	39
77	Strongyloides hyperinfection in adult T-cell leukaemia/lymphoma. British Journal of Haematology, 1999, 105, 1-1.	1.2	38
78	Guidelines on the use of colony-stimulating factors in haematological malignancies. British Journal of Haematology, 2003, 123, 22-33.	1.2	35
79	Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease. Bone Marrow Transplantation, 2008, 41, 831-832.	1.3	35
80	Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. Haematologica, 2009, 94, 956-966.	1.7	32
81	Cancer immunotherapy with CAR-T cells – behold the future. Clinical Medicine, 2018, 18, 324-328.	0.8	32
82	In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosispossible evidence of an occult myeloproliferative state. The Quarterly Journal of Medicine, 1990, 76, 981-9.	1.0	31
83	Hyperinfection with strongyloides after treatment for adult T cell leukaemia-lymphoma in an African immigrant BMJ: British Medical Journal, 1988, 297, 1456-1457.	2.4	30
84	Matching for 12 HLA Alleles Is Associated with a Significantly Superior Survival Due to a Lower Mortality in Recipients of Unrelated Donor Haematopoietic Cell Transplants for Early but Not Late Stage Leukaemia Blood, 2007, 110, 3056-3056.	0.6	30
85	An automated method for the simultaneous measurement of azole antifungal drugs in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2012, 404, 513-523.	1.9	29
86	A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. Leukemia, 2015, 29, 1478-1484.	3.3	29
87	Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells. Biology of Blood and Marrow Transplantation, 2017, 23, 293-299.	2.0	29
88	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. HemaSphere, 2021, 5, e612.	1.2	29
89	Mesenchymal stromal cells for acute graftâ€versusâ€host disease: response at 1Âweek predicts probability of survival. British Journal of Haematology, 2019, 185, 89-92.	1.2	28
90	Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 111-117.	2.0	27

#	Article	IF	CITATIONS
91	Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England. Blood, 2019, 134, 767-767.	0.6	27
92	Bilateral adrenal lymphoma presenting as Addison's disease Postgraduate Medical Journal, 1989, 65, 684-686.	0.9	26
93	Adult T-Cell Leukemia/Lymphoma in London: Clinical Experience of 21 Cases. Leukemia and Lymphoma, 1998, 31, 177-185.	0.6	26
94	Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplantation, 2006, 38, 823-824.	1.3	26
95	Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data. British Journal of Haematology, 2007, 136, 448-450.	1.2	26
96	Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. Bone Marrow Transplantation, 2014, 49, 704-708.	1.3	26
97	HTLV-I screening in Britain. BMJ: British Medical Journal, 1995, 311, 1313-1314.	2.4	25
98	Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM–CAMPATH (±) Tj ETQq0 0 0	) rgBT /Ov 0.3	erlock 10 Tf 24
99	The prevalence of the activating <i>JAK</i> 2 tyrosine kinase mutation in chronic portoâ€splenomesenteric venous thrombosis. Alimentary Pharmacology and Therapeutics, 2010, 31, 1330-1336.	1.9	24
100	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. International Journal of Hematologic Oncology, 2017, 6, 75-93.	0.7	24
101	Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions. Bone Marrow Transplantation, 2003, 31, 551-557.	1.3	23
102	Cardiac presentation of ALK positive anaplastic large cell lymphoma. European Journal of Haematology, 2005, 75, 511-514.	1.1	23
103	Lead poisoning: an age old problem BMJ: British Medical Journal, 1990, 300, 830-830.	2.4	22
104	Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Blood, 2017, 130, 887-887.	0.6	22
105	Acute liver failure as the initial manifestation of acute leukaemia. Liver, 2001, 21, 287-292.	0.1	21
106	Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. Journal of Infection, 2007, 54, e83-e86.	1.7	21
107	Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. Bone Marrow Transplantation, 2009, 44, 7-12.	1.3	21
108	Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome. Medical Mycology, 2016, 54, 691-698.	0.3	21

#	Article	IF	CITATIONS
109	The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. Biology of Blood and Marrow Transplantation, 2019, 25, 86-93.	2.0	21
110	Positron emission scanning with 18â€FDG in the diagnosis of deep fungal infections. British Journal of Haematology, 1998, 101, 392-393.	1.2	20
111	Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplantation, 2012, 47, 18-23.	1.3	20
112	Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK. Journal of Antimicrobial Chemotherapy, 2015, 70, 1175-1181.	1.3	20
113	PRODROMAL CUTANEOUS VASCULITIS IN MYELODYSPLASTIC SYNDROMES. British Journal of Haematology, 1990, 75, 444-446.	1.2	19
114	Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: Report of three cases and review of literature. Leukemia and Lymphoma, 2007, 48, 290-294.	0.6	19
115	Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). Leukemia Research, 2012, 36, 857-861.	0.4	19
116	Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 1342-1349.	2.0	19
117	Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients. Journal of Clinical Virology, 2020, 128, 104421.	1.6	19
118	Idiopathic hyperammonaemia syndrome following allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT). Bone Marrow Transplantation, 1997, 20, 1007-1008.	1.3	18
119	Fatal donor-derived Epstein–Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome. Bone Marrow Transplantation, 2002, 29, 867-869.	1.3	17
120	Disseminated herpes virus (HSV-2) infection with rhabdomyolysis and hemophagocytic lymphohistiocytosis in a patient with bone marrow failure syndrome. Annals of Hematology, 2006, 85, 629-630.	0.8	17
121	Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative. Bone Marrow Transplantation, 2008, 41, 587-588.	1.3	17
122	Composite biomarker panel for prediction of severity and diagnosis of acute GVHD with T-cell-depleted allogeneic stem cell transplants—single centre pilot study. Journal of Clinical Pathology, 2017, 70, 886-890.	1.0	17
123	Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Leukemia Research, 2009, 33, 244-249.	0.4	16
124	Measurement of Posaconazole, Itraconazole, and Hydroxyitraconazole in Plasma/Serum by High-Performance Liquid Chromatography With Fluorescence Detection. Therapeutic Drug Monitoring, 2011, 33, 735-741.	1.0	16
125	Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival. Bone Marrow Transplantation, 2007, 40, 747-752.	1.3	15
126	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica, 2023, 108, 22-33.	1.7	15

#	Article	IF	CITATIONS
127	Koebnerizing sclerodermatous graft-versus-host disease caused by donor lymphocyte infusion and interferon-α. British Journal of Dermatology, 2006, 155, 621-623.	1.4	14
128	Sarcoidosis and haematological malignancies: is there an association?. British Journal of Haematology, 2008, 141, 260-262.	1.2	14
129	Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis. Clinical Infectious Diseases, 2019, 69, 1757-1763.	2.9	14
130	SARS-CoV-2 infection in aplastic anemia. Haematologica, 2022, 107, 541-543.	1.7	14
131	Recurrent infections in sickle cell disease: haematological and immune studies. Clinica Chimica Acta, 1985, 148, 161-165.	0.5	13
132	Prodromal cutaneous lesions in adult T-cell leukaemia/lymphoma. Lancet, The, 1990, 335, 733-734.	6.3	13
133	An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. Cytotherapy, 2000, 2, 423-428.	0.3	13
134	Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin's lymphoma. Annals of Hematology, 2002, 81, 405-406.	0.8	13
135	Sarcoidosis as an unusual cause of hepatic dysfunction following reduced intensity conditioned allogeneic stem cell transplantation. Bone Marrow Transplantation, 2007, 39, 511-512.	1.3	13
136	Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. British Journal of Haematology, 2010, 149, 879-889.	1.2	13
137	Discrepancy between phenotype and genotype on screening for factor V Leiden after transplantation. Blood, 2001, 97, 2525-2526.	0.6	12
138	Multiple organ failure and severe bone marrow dysfunction in two 18 yearâ€old Caucasian patients: Epstein–Barr virus and the haemophagocytic syndrome. Anaesthesia, 2008, 63, 1249-1254.	1.8	11
139	Myelodysplasia syndromes during pregnancy. European Journal of Haematology, 1991, 47, 310-312.	1.1	11
140	Baseline cytokine profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation. Journal of Infection, 2016, 73, 280-288.	1.7	11
141	The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom. Journal of Medical Economics, 2020, 23, 86-97.	1.0	11
142	Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor α antibody). British Journal of Dermatology, 2006, 155, 617-620.	1.4	10
143	Mixed donor chimaerism in recipient fingernails following reduced-intensity conditioning haematopoietic SCT. Bone Marrow Transplantation, 2008, 42, 361-362.	1.3	10
144	A practical critique of antifungal treatment guidelines for haemato-oncologists. Critical Reviews in Microbiology, 2012, 38, 203-216.	2.7	10

#	Article	IF	CITATIONS
145	The "G-CSF test― Experimental Hematology, 1999, 27, 1204-1209.	0.2	9
146	Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200. Blood, 2003, 101, 779-780.	0.6	9
147	Life coaching following haematopoietic stem cell transplantation: a mixed-method investigation of feasibility and acceptability. European Journal of Cancer Care, 2015, 24, 531-541.	0.7	9
148	Early and late-onset veno-occlusive disease/sinusoidal syndrome post allogeneic stem cell transplantation – a real-world UK experience. American Journal of Transplantation, 2021, 21, 864-869.	2.6	9
149	Reduced Intensity Allogeneic Transplantation Using BEAM-Alemtuzumab in Patients with Lymphoid Malignancy: Long Term Results and Impact of Intervention with DLI Blood, 2005, 106, 2890-2890.	0.6	9
150	Trisomy 10 and acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2002, 134, 81-83.	1.0	8
151	Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI). Bone Marrow Transplantation, 2020, 55, 562-569.	1.3	8
152	Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—ls it prognostic?—a single-center retrospective study. Blood Cancer Journal, 2021, 11, 128.	2.8	8
153	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. Blood Advances, 2022, 6, 3870-3874.	2.5	8
154	Increase in allergy following donor lymphocyte infusions. Bone Marrow Transplantation, 2006, 37, 983-984.	1.3	7
155	The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis. Bone Marrow Transplantation, 2011, 46, 1210-1218.	1.3	7
156	Transplantâ€acquired food allergy ( <scp>TAFA</scp> ) following cord blood stem cell transplantation in two adult patients with haematological malignancies. British Journal of Haematology, 2014, 167, 426-428.	1.2	7
157	Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. Leukemia Research, 2014, 38, 737-743.	0.4	7
158	Are the risks of treatment to cure a child with severe sickle cell disease too high?. BMJ: British Medical Journal, 2017, 359, j5250.	2.4	7
159	Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Mycoses, 2017, 60, 79-88.	1.8	7
160	Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years. Blood Advances, 2019, 3, 3070-3079.	2.5	7
161	Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma. HemaSphere, 2021, 5, e535.	1.2	7
162	Patient/Donor CMV Matching Is a Critical Determinant of Survival in Unrelated Donor Haematopoietic Stem Cell Transplantation. Blood, 2014, 124, 1207-1207.	0.6	7

#	Article	IF	CITATIONS
163	Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML. Blood, 2015, 126, 347-347.	0.6	7
164	The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood, 2000, 96, 3932-3938.	0.6	7
165	A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results. Blood, 2021, 138, 749-749.	0.6	7
166	Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option. Bone Marrow Transplantation, 2022, 57, 959-965.	1.3	7
167	Palmar-plantar erythema associated with combination chemotherapy Postgraduate Medical Journal, 1990, 66, 242-243.	0.9	6
168	Colchicine: An Effective Treatment for Refractory Malignant Pericardial Effusion. Acta Haematologica, 2000, 104, 217-219.	0.7	6
169	Preâ€symptomatic (Baseline) computed tomography predicts invasive pulmonary aspergillosis in highâ€risk adult haematoâ€oncology patients. British Journal of Haematology, 2018, 182, 723-727.	1.2	6
170	Reduced Intensity Conditioned Volunteer Unrelated Donor Transplants Using Alemtuzumab Are Safe and Effective in Older Patients with Myelodysplastic Syndromes Blood, 2005, 106, 444-444.	0.6	6
171	Hypoplastic MDS Is a Distinct Clinico-Pathological Entity with Somatic Mutations Frequent in Patients with Prior Aplastic Anaemia with Favorable Clinical Outcome. Blood, 2014, 124, 3269-3269.	0.6	6
172	Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood, 2000, 96, 1239-1246.	0.6	6
173	Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting. Blood Advances, 2021, 5, 4500-4503.	2.5	6
174	Co-infection with HTLV-I/II and HIV-1. Lancet, The, 1990, 336, 383.	6.3	5
175	Blast counts in blood progenitor cell (BPC) collections correlate with CD34+ cells and CFU-GM and are a useful predictor of haemopoietic recovery after autologous BPC transplantation. Bone Marrow Transplantation, 1998, 21, 869-872.	1.3	5
176	T-cell lymphoblastic lymphoma presenting as an intra-muscular mass. British Journal of Haematology, 2006, 132, 537-537.	1.2	5
177	False positive results of galactomannan ELISA assay in haemato-oncology patients: A single centre experience. Journal of Infection, 2007, 55, 201-202.	1.7	5
178	Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM)–Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin Lymphoma: An Analysis of Outcomes from the British Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 483-488.	2.0	5
179	Alemtuzumab vs antiâ€thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning. European Journal of Haematology, 2018, 101, 466-474.	1.1	5
180	The role of a critical care outreach service in the management of patients with haematological malignancy. Journal of the Intensive Care Society, 2019, 20, 327-334.	1.1	5

#	Article	IF	CITATIONS
181	Pre-Emptive Donor Lymphocyte Infusions (DLI) Lead to High Cure Rates in T-Cell Depleted Allogeneic Haemopoietic Stem Cell Transplants for MDS/AML. Blood, 2011, 118, 660-660.	0.6	5
182	A Pooled Analysis of Survival By Defibrotide Timing of Initiation in Adults with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Following Hematopoietic Stem Cell Transplant (HSCT). Blood, 2018, 132, 815-815.	0.6	5
183	BEAM regimen and G-CSF in HTLV-I-associated T-cell lymphoma. Lancet, The, 1992, 339, 133-134.	6.3	4
184	22 Familial myelodysplastic syndromes: A key to understanding leukaemogenesis?. Leukemia Research, 1997, 21, S6.	0.4	4
185	Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-hodgkin's lymphoma. British Journal of Haematology, 2000, 110, 1013-1014.	1.2	4
186	The Kingscord model: a public cord blood collection service. British Journal of Midwifery, 2009, 17, 306-313.	0.1	4
187	Mucous membrane pemphigoid following reduced intensity conditioning allogeneic haematopoietic SCT for biphenotypic leukaemia. Bone Marrow Transplantation, 2010, 45, 195-196.	1.3	4
188	Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia – A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 242-245.	0.2	4
189	Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience. Frontiers in Oncology, 2019, 9, 623.	1.3	4
190	Coulter S Plus STKR histograms detect spurious elevation of leucocyte and platelet counts associated with cryoglobulinaemia. Blut, 1989, 59, 396-397.	1.2	3
191	Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy. Bone Marrow Transplantation, 2006, 38, 461-462.	1.3	3
192	Development of polycythaemia vera in a patient with myelofibrosis. European Journal of Haematology, 1989, 42, 96-98.	1.1	3
193	Comparative analysis of melphalan <i>versus</i> busulphan Tâ€cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia. British Journal of Haematology, 2019, 187, e20-e24.	1.2	3
194	Human parainfluenza virus type 3 infections in a haemato-oncology unit: social distancing measures needed in outpatient clinics. Journal of Hospital Infection, 2021, 116, 60-68.	1.4	3
195	Addition of Anti-Viral Therapy to Chemotherapy Improves Overall Survival In Acute and Lymphomatous Adult T-Cell Leukaemia/Lymphoma (ATLL). Blood, 2010, 116, 3961-3961.	0.6	3
196	Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort. Blood, 2019, 134, 4566-4566.	0.6	3
197	TREATMENT FOR MYELODYSPLASTIC SYNDROMES. Lancet, The, 1987, 330, 1095.	6.3	2
198	Warnings over cling film BMJ: British Medical Journal, 1991, 302, 593-593.	2.4	2

#	Article	IF	CITATIONS
199	Autologous Blood Stem Cell Transplantation in Hematological Malignancies. Leukemia and Lymphoma, 1994, 13, 33-40.	0.6	2
200	Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-hodgkin's lymphoma. British Journal of Haematology, 2000, 110, 1013-1014.	1.2	2
201	Non-Caseating Granulomata Associated with Hypocellular Myelodysplastic Syndrome. Leukemia and Lymphoma, 2000, 39, 397-403.	0.6	2
202	Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis. Leukemia Research, 2011, 35, 998-1000.	0.4	2
203	Analysis of Beam (Carmustine, Etoposide, Cytosine Arabinoside, Melphalan) Versus High Dose Melphalan (HDM) with Autologous Rescue in Multiple Myeloma(MM) Blood, 2004, 104, 5227-5227.	0.6	2
204	Equality Of Access To Transplant For Ethnic Minority Patients Through Use Of Cord Blood and Haploidentical Transplants. Blood, 2013, 122, 2138-2138.	0.6	2
205	Early Multilineage Chimerism Predicts The â€~Winning' Unit In Double Cord Blood Transplantation. Blood, 2013, 122, 300-300.	0.6	2
206	Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome Blood, 2005, 106, 2588-2588.	0.6	2
207	National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03). Blood, 2011, 118, 52-52.	0.6	2
208	King's College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd. Blood, 2014, 124, 1594-1594.	0.6	2
209	Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme. Blood, 2020, 136, 18-19.	0.6	2
210	Human parvovirus infection in sickle cell disease. Lancet, The, 1993, 342, 49.	6.3	1
211	Unrelated Cord Blood Transplantation in adults: evolution, experience and longâ€ŧerm outcomes in the <scp>UK</scp> National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. British Journal of Haematology, 2016, 172, 478-481.	1.2	1
212	Antiâ€type M phospholipase A2 receptor antibodyâ€positive membranous nephropathy as a part of multiâ€system autoimmune syndrome postâ€allogeneic stem cell transplantation. Internal Medicine Journal, 2018, 48, 481-483.	0.5	1
213	The importance of early intervention in the treatment of hepatic veno-occlusive disease. International Journal of Hematologic Oncology, 2019, 8, IJH15.	0.7	1
214	A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. Biology of Blood and Marrow Transplantation, 2019, 25, e270-e271.	2.0	1
215	Incidence of Post-Hematopoietic Stem Cell Transplantation (HSCT) Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) without Hyperbilirubinemia at Diagnosis and Efficacy of Defibrotide in an Expanded-Access Program. Blood, 2018, 132, 2080-2080.	0.6	1
216	Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT) Blood, 2004, 104, 1806-1806.	0.6	1

#	Article	IF	CITATIONS
217	Combination Chemotherapy with CHOP-Daclizumab in HTLV-I Associated Adult T-Cell Leukaemia/Lymphoma Blood, 2006, 108, 2750-2750.	0.6	1
218	HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS. Blood, 2012, 120, 4158-4158.	0.6	1
219	Feasibility and Optimal Schedule Of Using Eculizumab In Patients With Hemolytic Paroxysmal Nocturnal Hemoglobinuria (hPNH) With Severe Aplastic Anemia (SAA) Prior To Haemopoietic Stem Cell Transplant (HSCT). Blood, 2013, 122, 2482-2482.	0.6	1
220	Donor Attrition At The Confirmatory Typing Stage Results In Poorer Transplant Options For Patients Of All Ethnicities. Blood, 2013, 122, 3377-3377.	0.6	1
221	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients. Blood, 2014, 124, 1138-1138.	0.6	1
222	COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A) Tj ETQqO	0 <b>0.</b> 6gBT /	Overlock 10
223	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. Blood, 2020, 136, 6-8.	0.6	1
224	Aspergillus Infections. New England Journal of Medicine, 2022, 386, 198-199.	13.9	1
225	Chromosomal Analysis in Myelodysplastic Syndromes (Pre-Leukaemia): Introduced by AJ Bellingham. Clinical Science, 1989, 76, 13P-13P.	0.0	0
226	(B9) Childhood MDS in Turkey — clinical experience in 25 cases. Leukemia Research, 1991, 15, 5.	0.4	0
227	Is there a Role for Reduced-intensity Haematopoietic Stem Cell Transplantation for Indolent Non-Hodgkin's Lymphoma?. Hematology, 2002, 7, 345-354.	0.7	0
228	Response to Peggs et al Bone Marrow Transplantation, 2003, 31, 727-727.	1.3	0
229	Corrigendum to "Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation―[Journal of Infection 54 (2007) e83–e86]. Journal of Infection, 2007, 55, e11.	1.7	0
230	Alemtuzumab vs ATG for T-Cell Depletion in Sibling Donor Reduced Intensity Haematopoietic Stem Cell Transplantation (RIC HSCT) for the Treatment of Acute Myeloid Leukaemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2011, 17, S289.	2.0	0
231	Long Term Outcomes for Alemtuzumab Based Reduced Intensity Conditioning Transplant for Myelodysplastic Syndromes and Acute Myeloid Leukaemia. Biology of Blood and Marrow Transplantation, 2012, 18, S216.	2.0	0
232	S103â€Baseline CT thorax in patients undergoing allogeneic haematopoetic stem-cell transplantation and risk of invasive fungal disease- a prospective 5-year study. , 2021, , .		0
233	Single Centre Experience of Patients with Haematological Malignancies Admitted to Intensive Care Unit: A Comparative Review of Allogenic Bone Marrow Transplant Data Blood, 2004, 104, 1830-1830.	0.6	0
234	Invasive Pulmonary Aspergillosis Is Not a Contraindication to Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation (RIC allo-HSCT) Blood, 2004, 104, 1831-1831.	0.6	0

#	Article	IF	CITATIONS
235	Hematopoietic growth factors. , 2004, , 794-810.		0
236	Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Is as Effective in Poor Risk as Standard Risk Acute Myeloid Leukaemia (AML) Blood, 2005, 106, 2901-2901.	0.6	0
237	Matched Pair Analysis of Intravenous vs Oral Busulphan as Part of Fludarabine-Busulphan-Campath (Alemtuzumab) Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT) Blood, 2005, 106, 1762-1762.	0.6	0
238	Second Reduced Intensity Transplants Are Effective and Well Tolerated in Older Patients with Relapsed Myeloid Malignancies. A Single Centre Report Blood, 2005, 106, 5406-5406.	0.6	0
239	Improved Disease Free Survival Following Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Incorporating Alemtuzumab Compared with Autologous Stem Cell Transplantation in Follicular Lymphoma Blood, 2005, 106, 1144-1144.	0.6	0
240	The Outcome of Lymphoproliferative Disorder in Liver Transplant Recipients May Correlate with Age at Diagnosis and the Use of Chemotherapy: A Single Centre Report Blood, 2005, 106, 1435-1435.	0.6	0
241	Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Blood, 2006, 108, 3108-3108.	0.6	0
242	Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation Blood, 2007, 110, 1665-1665.	0.6	0
243	A Comparison of Stem Cell Source in Recipients of T-Cell Depleted Myeloablative Transplants for Leukaemia: No Difference in Mortality Using BM or PBSC Blood, 2007, 110, 46-46.	0.6	0
244	Results of a Phase I/II-Study on PCR-Based Pre-Emptive Therapy with Valganciclovir or Ganciclovir for Active CMV Infection Following Reduced Intensity Allogeneic Stem Cell Transplantation Blood, 2007, 110, 5011-5011.	0.6	0
245	Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI) Blood, 2007, 110, 3034-3034.	0.6	ο
246	A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab Blood, 2009, 114, 2266-2266.	0.6	0
247	Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Blood, 2010, 116, 1304-1304.	0.6	0
248	Pre-Surgical Methylene-Blue "targeting―of Small Intrapulmonary Nodules In Patients with Haematological Malignancies: Preliminary Experience Blood, 2010, 116, 4551-4551.	0.6	0
249	Cytokine Profile of Patients with Invasive Apsergillosis- Preliminary Results Blood, 2010, 116, 1500-1500.	0.6	0
250	Serum Ferritin and Cardiac/Liver Magnetic Resonance Imaging In Evaluating Iron Overload for Patients with Bone Marrow Failure Conditions Undergoing Non-Myeloablative HSCT. Blood, 2010, 116, 1331-1331.	0.6	0
251	Comparative Analysis of An Azacytidine Versus Azacytidine-HSCT Approach for the Treatment of Older Patients with AML/MDS. Blood, 2010, 116, 2375-2375.	0.6	0
252	Plerixafor Ex Vivo Mobilization of Placental Derived Haematopoietic Stem Cells. Blood, 2011, 118, 4790-4790.	0.6	0

#	Article	IF	CITATIONS
253	Long-Term Outcomes of Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation (RIC-HSCT) for AML with Myelodysplasia-Related Changes. Blood, 2011, 118, 3079-3079.	0.6	о
254	A Comprehensive Diagnostic Approach Improves the Diagnostic Accuracy of Invasive Fungal Disease (IFD) in Adult Haemato-Oncology Patients Undergoing HSCT or High Dose Chemotherapy- Results of the King's Prospective Aspergillosis Study (NCT00816088). Blood, 2011, 118, 2972-2972.	0.6	0
255	Outcome of BEAM-Autologous and BEAM-Alemtuzumab Allogeneic Transplantation in Relapsed Advanced Stage Follicular Lymphoma. Blood, 2012, 120, 2022-2022.	0.6	0
256	Allogeneic Stem Cell Transplantation for Accelerated/Blastic Phase Philadelphia-Chromosome Negative MPN. Blood, 2012, 120, 4532-4532.	0.6	0
257	Demethylating Agents As a Salvage Treatment in Relapsed Myeloid Diseases Following Allogeneic Bone Marrow Transplantation. Blood, 2012, 120, 4216-4216.	0.6	0
258	Adverse Effect of Very Poor Cytogenetics and Monosomal Karyotype On Outcomes Following T-Deplete Reduced Intensity Conditioned Stem Cell Transplant for MDS and AML Blood, 2012, 120, 3141-3141.	0.6	0
259	Non-Myeloablative Preparative Regimen in Children with Severe Organ Dysfunction Undergoing Bone Marrow Transplantation. Pediatric Research, 1999, 45, 768-768.	1.1	Ο
260	Increased Mortality in Patients with Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 2512-2512.	0.6	0
261	Busulfan-Dose Escalation in Reduced Intensity Stem Cell Transplantation (RIC-HSCT) Results in Good Outcomes for Patients with MDS and AML without Increased Toxicity. Blood, 2014, 124, 1236-1236.	0.6	0
262	Autologous Stem Cell Transplantation Achieves Long-Term Survival in a Selected CNS Lymphoma Population. Blood, 2014, 124, 1197-1197.	0.6	0
263	Immunological Profile of Patients after HSCT Using the FCC Conditioning Regimen for Treatment of Severe Aplastic Anemia Shows Sustained Mixed T-Cell Chimerism Is Due to Persistence of Recipient CD8 T Cells and Indicates Potential Basis for Tolerance and Extremely Low Incidence of Graft Versus Host Disease. Blood, 2015, 126, 3129-3129.	0.6	Ο
264	Donor Lymphocyte Infusions Correct Deficiency of Naive T Cells and Improve T-Cell Competence after Allogeneic Haematopoietic Stem Cell Transplantation with Lymphocyte Depletion. Blood, 2016, 128, 2233-2233.	0.6	0
265	Composite Biomarker Panel in Prediction of Severity and Diagnosis of Acute GvHD with T- Depleted Allogeneic Stem Cell Transplants- Single Centre Pilot Study. Blood, 2016, 128, 2234-2234.	0.6	Ο
266	Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience. Blood, 2019, 134, 4622-4622.	0.6	0
267	Optimising care for UK patients with acute myeloid leukaemia. British Journal of Hospital Medicine (London, England: 2005), 0, , 42-50.	0.2	0